Project description:Diffuse malignant peritoneal mesothelioma (DMPM) is a rapidly lethal malignancy. The comprehension of the molecular features of DMPM is of utmost importance for the fruitful management of the disease, especially in patients who fail standard treatments and have a poor prognosis due to the lack of effective alternative therapeutic options.
Project description:Malignant Peritoneal Mesothelioma (PeM) is a rare but frequently fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no targeted therapies for PeM yet exist. This study performs comprehensive integrative analysis of genome, transcriptome, and proteome of treatment-naïve PeM tumors with the aim of identifying mesothelioma-related molecular alterations and potentially identifying novel treatment strategies.
Project description:Diffuse malignant peritoneal mesothelioma (DMPM) is a rapidly lethal malignancy. The comprehension of the molecular and cellular features of DMPM is of utmost importance for the fruitful management of the disease, especially in patients who fail standard treatments and have a poor prognosis due to the lack of effective alternative therapeutic options. In this context, we previously found that telomerase activity (TA), which accounts for the limitless proliferative potential of cancer cells, is prognostic for disease relapse and cancer-related death in DMPM patients. Consequently, the identification of factors involved in telomerase activation/regulation may pave the way towards the development of novel therapeutic interventions for the disease. In the present study, miRNA expression profiling was carried out in a series of DMPM tissue specimens, previously characterized for the occurrence of TA, in order to possibly identify miRNAs that may play a role in the establishment/regulation of such a telomere maintenance mechanism in this malignancy and consequently furnish a biological rationale for the possible future development of miRNA-based telomerase-targeted therapeutic approaches.
Project description:Gene expression profiles were generated from 41 consecutive surgically resected fresh frozen malignant peritoneal mesothelioma patient tumor samples to identify molecular prognostic factors. Patient tumor samples hybridized against the common reference (complementary DNA generated from human universal RNA), 41 tumor samples.
Project description:FTIR based spectral histopathology was used for label-free classification of tumor tissue sections. The regions of interest were identified and annotated with high spatial resolution. The spatial information was used for automated laser capture microdissection of relevant tissue areas. Subsequently, the collected tissue samples were analyzed using quantitative proteomics. This novel approach for precise sample collection in clinical studies was applied to differentiate epitheloid and sarcomatoid subtypes of diffuse malignant mesothelioma.
Project description:Malignant Peritoneal Mesothelioma (PeM) is a rare but frequently fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no targeted therapies for PeM yet exist. This study performs comprehensive integrative analysis of genome, transcriptome, and proteome of treatment-naive PeM tumors with the aim of identifying mesothelioma-related molecular alterations and potentially identifying novel treatment strategies.
Project description:Intraperitoneal injection of crocidolite initiates malignant peritoneal mesothelioma (MM) in mice. We performed high-resolution comparative genomic hybridization to identify characterstics in the genomic profiles of crocidolite-induced MM in the mice.
Project description:Desmoplastic malignant mesothelioma is a rare tumor. Due to the rarity, genomic profile of desmoplastic malignant mesothelioma is not unveiled. To elucidate genomic profile of desmoplastic malignant mesothelioma, we used illumina infinium omini exomeexpress in an established patient-derived cell line of desmoplastic malignant mesothelioma.